EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current treatment landscape of acromegaly

Frederic Castinetti iD, Adriana G Ioachimescu iD

The Journal of Clinical Endocrinology & Metabolism · 04.06.2026 · 111 (Supplement_1) · S64-S76

DOI: 10.1210/clinem/dgag152 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.04.2026. Verfasst von Frederic Castinetti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Aix Marseille University, Marseille Medical Genetics, INSERM U1251 and Assistance Publique Hopitaux de Marseille, La Con…. Hauptthemen laut MEDLINE: Acromegaly. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of acromegaly includes surgery followed by chronic medical therapy for persistent growth hormone (GH) excess, and, in some patients, radiation. Treatment is aimed at biochemical normalization, which improves survival and comorbidities. However, many patients experience lifelong burden related to persistent acromegaly manifestations and adverse treatment effects. Long-acting somatostatin receptor ligand (SRL) therapy with octreotide or lanreotide has been the cornerstone of management. Pasireotide long-acting release, a somatostatin receptor multiligand, achieves more favorable biochemical control rates but is associated with an increased risk of hyperglycemia. Pegvisomant, a GH receptor antagonist, can be used as monotherapy or in combination with SRLs. The spectrum of medical therapy has expanded with the advent of oral octreotide capsules; the oral selective somatostatin receptor subtype 2 agonist, paltusotine; and monthly self-administered subcutaneous octreotide. This review outlines the updates to current acromegaly treatment options and their impact on patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyHumansSomatostatinOctreotideHuman Growth HormoneReceptors, Somatostatin

Stichwörter der Autor:innen

paltusotinepasireotidepegvisomantradiotherapysomatostatin receptor ligandstranssphenoidal surgery

Substanzen

SomatostatinOctreotideHuman Growth HormonepegvisomantReceptors, Somatostatin

Autor:innen und Institutionen

  • Department of Endocrinology, Aix Marseille University, Marseille Medical Genetics, INSERM U1251 and Assistance Publique Hopitaux de Marseille, La Conception Hospital, French Reference Center for Rare Pituitary Diseases…
  • Division of Endocrinology and Molecular Medicine, Department of Medicine and Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

ORCID-Profile: Frederic Castinetti, Adriana G Ioachimescu

Zitieren

APA

Castinetti, F., & Ioachimescu, A. G. (2026). Current treatment landscape of acromegaly. The Journal of Clinical Endocrinology & Metabolism, 111(Supplement_1), S64-S76. https://doi.org/10.1210/clinem/dgag152

Vancouver

Castinetti F, Ioachimescu AG. Current treatment landscape of acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2026;111(Supplement_1):S64-S76. doi:10.1210/clinem/dgag152

BibTeX
@article{Castinetti2026,
  author = {Castinetti, Frederic and Ioachimescu, Adriana G},
  title = {Current treatment landscape of acromegaly},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {Supplement_1},
  pages = {S64--S76},
  doi = {10.1210/clinem/dgag152}
}
Kostenlos starten →